» Articles » PMID: 29982525

Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment

Overview
Journal Endocr Rev
Specialty Endocrinology
Date 2018 Jul 9
PMID 29982525
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Infertility affects one in six of the population and increasingly couples require treatment with assisted reproductive techniques. In vitro fertilization (IVF) treatment is most commonly conducted using exogenous FSH to induce follicular growth and human chorionic gonadotropin (hCG) to induce final oocyte maturation. However, hCG may cause the potentially life-threatening iatrogenic complication "ovarian hyperstimulation syndrome" (OHSS), which can cause considerable morbidity and, rarely, even mortality in otherwise healthy women. The use of GnRH agonists (GnRHas) has been pioneered during the last two decades to provide a safer option to induce final oocyte maturation. More recently, the neuropeptide kisspeptin, a hypothalamic regulator of GnRH release, has been investigated as a novel inductor of oocyte maturation. The hormonal stimulus used to induce oocyte maturation has a major impact on the success (retrieval of oocytes and chance of implantation) and safety (risk of OHSS) of IVF treatment. This review aims to appraise experimental and clinical data of hormonal approaches used to induce final oocyte maturation by hCG, GnRHa, both GnRHa and hCG administered in combination, recombinant LH, or kisspeptin. We also examine evidence for the timing of administration of the inductor of final oocyte maturation in relationship to parameters of follicular growth and the subsequent interval to oocyte retrieval. In summary, we review data on the efficacy and safety of the major hormonal approaches used to induce final oocyte maturation in clinical practice, as well as some novel approaches that may offer fresh alternatives in future.

Citing Articles

Explainable artificial intelligence to identify follicles that optimize clinical outcomes during assisted conception.

Hanassab S, Nelson S, Akbarov A, Yeung A, Hramyka A, Alhamwi T Nat Commun. 2025; 16(1):296.

PMID: 39779682 PMC: 11711444. DOI: 10.1038/s41467-024-55301-y.


Dual trigger versus human chorionic gonadotropin trigger for blastocyst quality and cumulative live birth.

He Z, Liu Y, Huang N, Liu X, Zeng L, Lian Y J Assist Reprod Genet. 2024; 41(12):3445-3453.

PMID: 39549203 PMC: 11707115. DOI: 10.1007/s10815-024-03293-5.


Rescue intrauterine insemination in women failing to retrieve oocytes at ovum pick-up: report of a case series.

Muzii L, Galati G, La Barbiera I, Linari A, Capri O, Pietrangeli D J Assist Reprod Genet. 2024; 41(6):1527-1530.

PMID: 38635024 PMC: 11224174. DOI: 10.1007/s10815-024-03091-z.


The prospect of artificial intelligence to personalize assisted reproductive technology.

Hanassab S, Abbara A, Yeung A, Voliotis M, Tsaneva-Atanasova K, Kelsey T NPJ Digit Med. 2024; 7(1):55.

PMID: 38429464 PMC: 10907618. DOI: 10.1038/s41746-024-01006-x.


Detecting partial premature ovulation during follicular aspiration compromises the quantity, but not the quality, of the oocytes retrieved in stimulated in vitro fertilization (IVF) cycles.

Gomez V, Rodriguez-Varela C, Labarta E, Bosch E JBRA Assist Reprod. 2024; 28(2):240-246.

PMID: 38289203 PMC: 11152434. DOI: 10.5935/1518-0557.20240003.


References
1.
Matorras R, Meabe A, Mendoza R, Prieto B, Ramon O, Mugica J . Human chorionic gonadotropin (hCG) plasma levels at oocyte retrieval and IVF outcomes. J Assist Reprod Genet. 2012; 29(10):1067-71. PMC: 3492576. DOI: 10.1007/s10815-012-9826-7. View

2.
Kim C, Ahn J, You R, Kim S, Chae H, Kang B . Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization. J Reprod Med. 2014; 59(1-2):63-8. View

3.
le Cotonnec J, Porchet H, Beltrami V, Munafo A . Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril. 1998; 69(2):189-94. DOI: 10.1016/s0015-0282(97)00501-3. View

4.
Pereira N, Elias R, Neri Q, Gerber R, Lekovich J, Palermo G . Adjuvant gonadotrophin-releasing hormone agonist trigger with human chorionic gonadotrophin to enhance ooplasmic maturity. Reprod Biomed Online. 2016; 33(5):568-574. DOI: 10.1016/j.rbmo.2016.08.009. View

5.
Wang W, Zhang X, Wang W, Liu Y, Zhao L, Xue S . The time interval between hCG priming and oocyte retrieval in ART program: a meta-analysis. J Assist Reprod Genet. 2011; 28(10):901-10. PMC: 3220445. DOI: 10.1007/s10815-011-9613-x. View